Assessment of Ocular Pharmacokinetics and Safety of Ganciclovir Loaded Nanoformulations

Abstract

Ganciclovir (GCV) plays an important role in the treatment of ocular viral infections. A high dose results in dose-related toxicity including bone marrow suppression and neutropenia. The aim of the present study was to investigate the comparative potential of different mucoadhesive nano formulations for the topical ocular delivery of Ganciclovir. GCV mucoadhesive Nanoemulsions (GCV-NEs), chitosan nanoparticles (GCV-NPs), GCV mucoadhesive niosomal dispersion (GCV-NDs) were prepared by the reverse-phase evaporation technique. All of the three formulations were evenly round in shape with mean particle size in the range of 23-200 nm. These results indicated the nonirritant and nontoxic nature of the developed formulations. The achieved results may be useful for formulation development of GCV, which could be effective in the treatment of ocular infections by topical instillation.

Drug delivery methods based on nanotechnology for the treatment of eye diseases

“…Inflammation, ocular heat, redness, irritation, conjunctival chemosis, and corneal opacity are symptoms of ocular intolerance and toxicity. An infrared camera may be used to evaluate an inflammatory process if the temperature of the ocular surface increases 74 . Ocular toxicity is detected in the HET-CAM test by irritation, haemorrhage, and coagulation in the chorio-allantoic membrane of a fertilised chicken egg 72 .…”

New Advances in Nanomaterial‐Based Antiviral Strategies

“…Remarkably, ganciclovir‐loaded organic nanomaterials, including GCV mucoadhesive nanoemulsions, GCV chitosan NPs, and GCV mucoadhesive niosomal dispersions, can reduce drug toxicity and provide higher ocular bioavailability. [ 71 ] A liver‐targeted dendritic nanocarrier functionalized with a galactopyranoside ligand can deliver siRNA against the conserved 5’‐untranslated region (UTR) of HCV RNA. The preferential delivery of anti‐HCV siRNA to the liver was achieved due to the highly specific ligand‐receptor interaction of dendritic galactose and the asialoglycoprotein receptors on liver cells.…”

Nanomedicines as Cancer Therapeutics: Current Status

“…Nonionic surfactant-based vesicles (NSVs) are now one of the most widely studied alternatives to liposomes, resulting from the self-assembly of hydrated surfactants monomers. Surfactants can be employed as useful surrogates to phospholipids in the fabrication of vesicular systems [65,66], and have some advantages over liposomes like avoidance of superfluous use of phospholipid (vulnerable to oxidative degradation) thereby boosting formulation stability, and drastic reduction in production cost. The rationale behind using niosomes in anticancer therapy is to prolong the circulation of entrapped drug, altering its organ distribution and metabolic stability, as well as to reduce drug-induced toxic effects to extra-tumorous tissues.…”